论文部分内容阅读
目的:初步探讨清肺合剂对中青年及老年原发性肺癌患者的临床疗效及生存状况。方法:选择2003年1月—2008年12月间收治的肺癌病人中,连续服用清肺合剂3年以上的原发性肺癌患者120例,分别入组中青年组和老年组,分析其临床特点构成和生存状况。结果:120例肺癌患者中,64.17%的中晚期肺癌患者的生存率达3年以上,高于同类文献报道。中青年组和老年组的临床构成比中吸烟、病理类型、治疗方式、TNM分期等因素具有统计学意义。清肺合剂对青年人肺癌和非青年人肺癌的咳嗽、咳痰、痰血、胸痛等有效缓解率达70%以上,对两组人群的临床症状改善情况无明显差异。结论:清肺合剂在改善患者的临床症状,提高生活质量等方面已得到证实,但对于肺癌手术后及放、化疗后的长期预防治疗及是否有延长生存期的作用,还有待进一步证实。
Objective: To investigate the clinical efficacy and survival of Qingfei Mixture on middle-aged and young patients with primary lung cancer. Methods: Among the patients with lung cancer admitted from January 2003 to December 2008, 120 patients with primary lung cancer who took Qingfei Mix more than 3 years continuously were enrolled in the middle-aged and young patients and the elderly patients respectively. The clinical features Composition and living conditions. Results: Of 120 patients with lung cancer, 64.17% of patients with advanced lung cancer had a survival rate of over 3 years, which was higher than that reported in the same literature. The clinical composition ratio of middle-aged and young group was statistically significant compared with smoking, pathological type, treatment, TNM staging and other factors. Qingfei Mixture can effectively relieve the cough, sputum, sputum, chest pain and other effective rates of lung cancer and non-young lung cancer in young people over 70%. There is no significant difference in the clinical symptoms between the two groups. Conclusion: Qingfei Mixture has been confirmed in improving clinical symptoms and improving quality of life. However, it remains to be confirmed whether long-term preventive and therapeutic effects after lung cancer surgery and radiotherapy and chemotherapy and whether prolongation of survival time are needed.